Glass manufacturer Asahi Glass Co. Ltd. will integrate its bioscience business, unifying its bioscience contract development and manufacturing organization (CDMO) subsidiaries under the AGC Biologics name. The company has set up its center of operations in Seattle and appointed Gustavo Mahler, CEO of CMC Biologics, as head of the integrated bioscience operations. The corporate names of CMC Biologics and Biomeva GmbH will also be changed to AGC Biologics. AGC made its first foray into bioscience-related business in 1985 and launched its first contract pharmaceutical manufacturing business in 2000 by operating a microorganism-based CDMO that operated mostly in Japan. AGC acquired Biomeva in 2016 and acquired CMC Biologics in 2017, establishing a three-branch structure for the group's bioscience operations. AGC operated mainly in Japan and other countries in Asia; Biomeva mainly in Europe; and CMC Biologics mainly in North and South America and Europe. Through this current business integration effort, AGC will centralize the core functions at a single location, unifying quality standards and operating methods. This move aims to provide clients with a smooth, consistent interface and high-quality services.